{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:57:25Z","timestamp":1783979845246,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,7]]},"DOI":"10.7759\/cureus.96335","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T01:48:54Z","timestamp":1762566534000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Slowly Progressive Type 1 Diabetes Mellitus (SPIDDM, Probable) Successfully Managed With Oral Semaglutide for Glycemic Control and Weight Management Accompanied by Changes in Eating Behavior"],"prefix":"10.7759","author":[{"given":"Taro","family":"Hirai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munehiro","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"Katsarou A","year":"2017","unstructured":"Katsarou A, Gudbj\u00f6rnsdottir S, Rawshani A, et al.. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017, 3:17016. 10.1038\/nrdp.2017.16","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14121","article-title":"New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): report from Committee on Type 1 Diabetes of the Japan Diabetes Society (English version)","volume":"15","author":"Shimada A","year":"2024","unstructured":"Shimada A, Kawasaki E, Abiru N, et al.. New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): report from Committee on Type 1 Diabetes of the Japan Diabetes Society (English version). J Diabetes Investig. 2024, 15:254-7. 10.1111\/jdi.14121","journal-title":"J Diabetes Investig"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S191007","article-title":"Slowly progressive type 1 diabetes mellitus: current knowledge and future perspectives","volume":"12","author":"Nishimura A","year":"2019","unstructured":"Nishimura A, Matsumura K, Kikuno S, Nagasawa K, Okubo M, Mori Y, Kobayashi T. Slowly progressive type 1 diabetes mellitus: current knowledge and future perspectives. Diabetes Metab Syndr Obes. 2019, 12:2461-77. 10.2147\/DMSO.S191007","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2267","article-title":"Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus","volume":"93","author":"Maruyama T","year":"2008","unstructured":"Maruyama T, Tanaka S, Shimada A, et al.. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab. 2008, 93:2115-21. 10.1210\/jc.2007-2267","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst JJ","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007, 87:1409-39. 10.1152\/physrev.00034.2006","journal-title":"Physiol Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","year":"2025","unstructured":"9. Pharmacologic approaches to glycemic treatment. standards of care in diabetes-2025. Diabetes Care. 2025, 48:S181-206. 10.2337\/dc25-S009","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT one treat-to-target randomized trial","volume":"39","author":"Mathieu C","year":"2016","unstructured":"Mathieu C, Zinman B, Hemmingsson JU, et al.. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT one treat-to-target randomized trial. Diabetes Care. 2016, 39:1702-10. 10.2337\/dc16-0691","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ23-0593","article-title":"Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan","volume":"71","author":"Ogawa W","year":"2024","unstructured":"Ogawa W, Hirota Y, Miyazaki S, et al.. Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan. Endocr J. 2024, 71:223-31. 10.1507\/endocrj.EJ23-0593","journal-title":"Endocr J"},{"key":"ref9","article-title":"Guidelines for the Management of Obesity Disease 2022 (In Japanese)","author":"Japan Society for the Study of Obesity","year":"2022","unstructured":"Japan Society for the Study of Obesity. Guidelines for the Management of Obesity Disease 2022 (In Japanese).  Life Science Publishing Company, Tokyo, Japan; 2022. 5:65."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12020147","article-title":"Glucagon-like peptide-1 receptor agonist semaglutide improves eating behavior and glycemic control in Japanese obese type 2 diabetic patients","volume":"12","author":"Masaki T","year":"2022","unstructured":"Masaki T, Ozeki Y, Yoshida Y, Okamoto M, Miyamoto S, Gotoh K, Shibata H. Glucagon-like peptide-1 receptor agonist semaglutide improves eating behavior and glycemic control in Japanese obese type 2 diabetic patients. Metabolites. 2022, 12:10.3390\/metabo12020147","journal-title":"Metabolites"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"44","author":"Holt RI","year":"2021","unstructured":"Holt RI, DeVries JH, Hess-Fischl A, et al.. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021, 44:2589-625. 10.2337\/dci21-0043","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14255","article-title":"Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes","volume":"23","author":"Gibbons C","year":"2021","unstructured":"Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab. 2021, 23:581-8. 10.1111\/dom.14255","journal-title":"Diabetes Obes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell J","year":"2017","unstructured":"Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017, 19:1242-51. 10.1111\/dom.12932","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0849","article-title":"GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans","volume":"63","author":"van Bloemendaal L","year":"2014","unstructured":"van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al.. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014, 63:4186-96. 10.2337\/db14-0849","journal-title":"Diabetes"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0772","article-title":"Liraglutide reduces CNS activation in response to visual food cues only after short-term treatment in patients with type 2 diabetes","volume":"39","author":"Ten Kulve JS","year":"2016","unstructured":"Ten Kulve JS, Veltman DJ, van Bloemendaal L, Barkhof F, Drent ML, Diamant M, IJzerman RG. Liraglutide reduces CNS activation in response to visual food cues only after short-term treatment in patients with type 2 diabetes. Diabetes Care. 2016, 39:214-21. 10.2337\/dc15-0772","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0490","article-title":"Efficacy of semaglutide in overweight and obese patients with type 1 diabetes","volume":"26","author":"Garg SK","year":"2024","unstructured":"Garg SK, Kaur G, Haider Z, Rodriquez E, Beatson C, Snell-Bergeon J. Efficacy of semaglutide in overweight and obese patients with type 1 diabetes. Diabetes Technol Ther. 2024, 26:184-9. 10.1089\/dia.2023.0490","journal-title":"Diabetes Technol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-013-0034-y","article-title":"Adherence to therapies in patients with type 2 diabetes","volume":"4","author":"Garc\u00eda-P\u00e9rez LE","year":"2013","unstructured":"Garc\u00eda-P\u00e9rez LE, Alvarez M, Dilla T, Gil-Guill\u00e9n V, Orozco-Beltr\u00e1n D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013, 4:175-94. 10.1007\/s13300-013-0034-y","journal-title":"Diabetes Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.14267","article-title":"Practice guideline: statement regarding treatment for suspected slowly progressive type\u20091 diabetes (SPIDDM; probable) cases (English version)","volume":"16","author":"Shimada A","year":"2025","unstructured":"Shimada A, Kawasaki E, Abiru N, et al.. Practice guideline: statement regarding treatment for suspected slowly progressive type\u20091 diabetes (SPIDDM; probable) cases (English version). J Diabetes Investig. 2025, 16:163-8. 10.1111\/jdi.14267","journal-title":"J Diabetes Investig"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1021\/pr400527q","article-title":"Glucagon-like peptide-1 protects human islets against cytokine-mediated \u03b2-cell dysfunction and death: a proteomic study of the pathways involved","volume":"12","author":"Rondas D","year":"2013","unstructured":"Rondas D, Bugliani M, D'Hertog W, et al.. Glucagon-like peptide-1 protects human islets against cytokine-mediated \u03b2-cell dysfunction and death: a proteomic study of the pathways involved. J Proteome Res. 2013, 12:4193-206. 10.1021\/pr400527q","journal-title":"J Proteome Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15889","article-title":"Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): a randomized, double-blind, placebo-controlled trial","volume":"26","author":"Dejgaard TF","year":"2024","unstructured":"Dejgaard TF, Frandsen CS, Kielgast U, et al.. Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2024, 26:4905-15. 10.1111\/dom.15889","journal-title":"Diabetes Obes Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/397347-a-case-of-slowly-progressive-type-1-diabetes-mellitus-spiddm-probable-successfully-managed-with-oral-semaglutide-for-glycemic-control-and-weight-management-accompanied-by-changes-in-eating-behavior","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T01:48:54Z","timestamp":1762566534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/397347-a-case-of-slowly-progressive-type-1-diabetes-mellitus-spiddm-probable-successfully-managed-with-oral-semaglutide-for-glycemic-control-and-weight-management-accompanied-by-changes-in-eating-behavior"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.96335","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,7]]}}}